In addition, although FGFR2 immunostaining in cholangiocarcinoma has been reported, the sensitivity of FGFR immunostaining remains low, with a sensitivity of 57.1% and a specificity of 97.7% according to Uson et al. Since NMIBC accounts for approximately 70–80% of bladder cancers, the evaluation of FGFR3 in MIBC may be inadequate [24]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.